PUBLISHER: Persistence Market Research | PRODUCT CODE: 1478009
PUBLISHER: Persistence Market Research | PRODUCT CODE: 1478009
Statins Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
Persistence Market Research offers a detailed analysis of the global Statins Market, providing insights into market dynamics, key growth drivers, challenges, and emerging trends. The report serves as a comprehensive guide for stakeholders, offering in-depth data and statistics for navigating the market landscape from 2024 to 2031.
The global statins market is projected to grow significantly between 2024 and 2031, with an expected CAGR of 3.5% during this period. The market is estimated to increase from a value of USD 16.63 billion in 2024 to USD 21.15 billion by the end of 2031.
Key Insights:
- Estimated Market Value (2024): USD 16.63 Billion
- Projected Market Value (2031): USD 21.15 Billion
- Global Market Growth Rate (CAGR 2024 to 2031): 3.5%
Statins Market - Report Scope:
Statins, widely used to manage high cholesterol levels, are pivotal in reducing the risk of cardiovascular diseases. The increase in lifestyle-related disorders, such as obesity and diabetes, drives the demand for statins. Statins lower cholesterol by inhibiting HMG-CoA reductase, a key enzyme involved in cholesterol synthesis. With cardiovascular diseases remaining a leading cause of mortality worldwide, the adoption of statins is expected to grow.
Healthcare policies and guidelines promote statin usage for preventive measures, particularly among at-risk populations. The aging global population, combined with rising healthcare awareness, underscores the need for effective cholesterol management, contributing to the steady growth of the statins market.
Market Growth Drivers:
The statins market is driven by several factors, including the increasing prevalence of cardiovascular diseases and related risk factors like obesity, hypertension, and diabetes. Additionally, the growing geriatric population, more susceptible to heart diseases, fuels demand for cholesterol-lowering therapies. Public health campaigns promoting the importance of cardiovascular health and cholesterol management further bolster the market.
Technological advancements in drug formulations lead to improved patient outcomes, encouraging greater adoption of statins. Moreover, the expanding use of statins in emerging markets, where cardiovascular disease rates are rising, represents a significant growth opportunity.
Market Restraints:
Despite its positive growth outlook, the statins market faces some restraints. Concerns about potential side effects, such as muscle pain, liver damage, and increased diabetes risk, can affect patient compliance and deter physicians from prescribing statins. Regulatory changes and stringent approval processes for new statin drugs can also slow market growth.
Additionally, the presence of generic statins affects market dynamics by creating pricing pressure for branded products. This can limit profit margins for pharmaceutical companies, impacting their ability to invest in research and development for new statins or combination therapies.
Market Opportunities:
The statins market presents several opportunities for innovation and expansion. Combination therapies that pair statins with other cardiovascular medications are gaining popularity due to their potential for enhanced therapeutic effects. There is also a growing interest in personalized medicine, where statin therapy is tailored to individual patient needs based on genetic markers and risk profiles.
Emerging markets offer significant growth potential, as the prevalence of cardiovascular diseases rises and healthcare infrastructure improves. Companies that can effectively market and distribute statins in these regions are likely to see substantial growth.
Key Questions Addressed in the Report:
- What is the Expected Value CAGR of the Statins Market from 2024 to 2031?
- What are the Key Factors Driving the Growth of the Statins Market?
- Which Region Holds the Largest Market Share in the Statins Market?
- Who are the Key Players in the Global Statins Market?
- What Strategies are Adopted by Leading Companies to Sustain Growth in the Statins Market?
Competitive Landscape and Business Strategies:
Leading companies in the statins market include Pfizer, Inc., AstraZeneca, and Merck & Co., Inc. These companies focus on product innovation, research and development, and strategic collaborations to maintain their competitive edge. Pfizer's Lipitor (atorvastatin) and AstraZeneca's Crestor (rosuvastatin) are among the most well-known statin brands, driving significant market share.
Strategies such as strategic partnerships, mergers, and acquisitions are employed to expand market presence and gain access to new markets. Companies are also investing in clinical trials to demonstrate the efficacy and safety of statins, fostering confidence among healthcare professionals and patients.
Key Companies Profiled:
- Pfizer, Inc.
- AstraZeneca
- Merck & Co., Inc.
- Novartis International AG
- Sanofi S.A.
- Eli Lilly and Company
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc.
- AbbVie Inc.
Statins Market Segmentation:
By Drug Class:
- Astrovastatins
- Fluvastatins
- Lovastatins
- Pravastatins
- Simvastatins
- Others
By Therapeutic Treatment:
- Cardiovascular Disorders
- Obesity
- Inflammatory Disorders
- Others
By End User:
- Hospitals
- Clinics
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Table of Contents
1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand Side Trends
- 1.3. Supply Side Trends
- 1.4. Technology Roadmap
- 1.5. Analysis and Recommendations
2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Product Innovation / Development Trends
4. Key Success Factors
- 4.1. Product Adoption / Usage Analysis
- 4.2. Product USPs / Features
- 4.3. Strategic Promotional Strategies
5. Global Statins Market Demand Analysis 2019-2023 and Forecast, 2024-2031
- 5.1. Historical Market Volume (Tons) Analysis, 2019-2023
- 5.2. Current and Future Market Volume (Tons) Projections, 2024-2031
- 5.3. Y-o-Y Growth Trend Analysis
6. Global Statins Market - Pricing Analysis
- 6.1. Regional Pricing Analysis By Drug Class
- 6.2. Global Average Pricing Analysis Benchmark
7. Global Statins Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031
- 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
- 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis
8. Market Background
- 8.1. Macro-Economic Factors
- 8.1.1. Global GDP Growth Outlook
- 8.1.2. Global Industry Value Added Overview
- 8.1.3. Global Infrastructure Investment Overview
- 8.1.4. Global Construction Spending Analysis
- 8.1.5. Other Macro Economic Factors
- 8.2. Forecast Factors - Relevance & Impact
- 8.2.1. Top Companies Historical Growth
- 8.2.2. GDP Growth forecast
- 8.2.3. Construction Industry forecast
- 8.2.4. End User Growth Outlook
- 8.2.5. Collaboration Activities
- 8.3. Value Chain
- 8.3.1. Raw Material Suppliers
- 8.3.2. List of Manufacturers
- 8.3.3. List of Distributors
- 8.4. COVID-19 Crisis - Impact Assessment
- 8.4.1. Current Statistics
- 8.4.2. Short-Mid-Long Term Outlook
- 8.4.3. Likely Rebound
- 8.5. Market Dynamics
- 8.5.1. Drivers
- 8.5.2. Restraints
- 8.5.3. Opportunity Analysis
- 8.5.4. Trends
9. Global Statins Market Analysis 2019-2023 and Forecast 2024-2031, by Drug Class
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Mn) and Volume Analysis by Type, 2019-2023
- 9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast by Drug Class 2024-2031
- 9.3.1. Astrovastatins
- 9.3.2. Fluvastatins
- 9.3.3. Lovastatins
- 9.3.4. Pravastatins
- 9.3.5. Simvastatins
- 9.3.6. Others
- 9.4. Market Attractiveness Analysis by Drug Class
10. Global Statins Market Analysis 2019-2023 and Forecast 2024-2031, By Therapeutic Treatment
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Mn) and Volume Analysis By Therapeutic Treatment, 2019-2023
- 10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Therapeutic Treatment, 2024-2031
- 10.3.1. Cardiovascular Disorders
- 10.3.2. Obesity
- 10.3.3. Inflammatory Disorders
- 10.3.4. Others
- 10.4. Market Attractiveness Analysis By Therapeutic Treatment
11. Global Statins Market Analysis 2019-2023 and Forecast 2024-2031, By End User
- 11.1. Introduction / Key Findings
- 11.2. Historical Market Size (US$ Mn) and Volume Analysis By End User, 2019-2023
- 11.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By End User 2024-2031
- 11.3.1. Hospitals
- 11.3.2. Clinics
- 11.4. Market Attractiveness Analysis By End User
12. Global Statins Market Analysis 2019-2023 and Forecast 2024-2031, by Region
- 12.1. Introduction
- 12.2. Historical Market Size (US$ Mn) and Volume Analysis by Region, 2019-2023
- 12.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast by Region, 2024-2031
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. East Asia
- 12.3.5. South Asia and Pacific
- 12.3.6. Middle East and Africa (MEA)
- 12.4. Market Attractiveness Analysis By Region
13. North America Statins Market Analysis 2019-2023 and Forecast 2024-2031
- 13.1. Introduction
- 13.2. Pricing Analysis
- 13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
- 13.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
- 13.4.1. By Country
- 13.4.1.1. U.S.
- 13.4.1.2. Canada
- 13.4.2. By Type
- 13.4.3. By Therapeutic Treatment
- 13.4.4. By End User
- 13.4.1. By Country
- 13.5. Market Attractiveness Analysis
- 13.5.1. By Country
- 13.5.2. By Type
- 13.5.3. By Therapeutic Treatment
- 13.5.4. By End User
- 13.6. Market Trends
- 13.7. Key Market Participants - Intensity Mapping
- 13.8. Drivers and Restraints - Impact Analysis
14. Latin America Statins Market Analysis 2019-2023 and Forecast 2024-2031
- 14.1. Introduction
- 14.2. Pricing Analysis
- 14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
- 14.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
- 14.4.1. By Country
- 14.4.1.1. Brazil
- 14.4.1.2. Mexico
- 14.4.1.3. Rest of Latin America
- 14.4.2. By Type
- 14.4.3. By Therapeutic Treatment
- 14.4.4. By End User
- 14.4.1. By Country
- 14.5. Market Attractiveness Analysis
- 14.5.1. By Country
- 14.5.2. By Type
- 14.5.3. By Therapeutic Treatment
- 14.5.4. By End User
- 14.6. Market Trends
- 14.7. Key Market Participants - Intensity Mapping
- 14.8. Drivers and Restraints - Impact Analysis
15. Europe Statins Market Analysis 2019-2023 and Forecast 2024-2031
- 15.1. Introduction
- 15.2. Pricing Analysis
- 15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
- 15.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
- 15.4.1. By Country
- 15.4.1.1. Germany
- 15.4.1.2. Italy
- 15.4.1.3. France
- 15.4.1.4. U.K.
- 15.4.1.5. Spain
- 15.4.1.6. BENELUX
- 15.4.1.7. Russia
- 15.4.1.8. Rest of Europe
- 15.4.2. By Type
- 15.4.3. By Therapeutic Treatment
- 15.4.4. By End User
- 15.4.1. By Country
- 15.5. Market Attractiveness Analysis
- 15.5.1. By Country
- 15.5.2. By Type
- 15.5.3. By Therapeutic Treatment
- 15.5.4. By End User
- 15.6. Market Trends
- 15.7. Key Market Participants - Intensity Mapping
- 15.8. Drivers and Restraints - Impact Analysis
16. South Asia and Pacific Statins Market Analysis 2019-2023 and Forecast 2024-2031
- 16.1. Introduction
- 16.2. Pricing Analysis
- 16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
- 16.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
- 16.4.1. By Country
- 16.4.1.1. India
- 16.4.1.2. ASEAN
- 16.4.1.3. Oceania
- 16.4.1.4. Rest of South Asia & Pacific
- 16.4.2. By Type
- 16.4.3. By Therapeutic Treatment
- 16.4.4. By End User
- 16.4.1. By Country
- 16.5. Market Attractiveness Analysis
- 16.5.1. By Country
- 16.5.2. By Type
- 16.5.3. By Therapeutic Treatment
- 16.5.4. By End User
- 16.6. Market Trends
- 16.7. Key Market Participants - Intensity Mapping
- 16.8. Drivers and Restraints - Impact Analysis
17. East Asia Statins Market Analysis 2019-2023 and Forecast 2024-2031
- 17.1. Introduction
- 17.2. Pricing Analysis
- 17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
- 17.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
- 17.4.1. By Country
- 17.4.1.1. China
- 17.4.1.2. Japan
- 17.4.1.3. South Korea
- 17.4.2. By Type
- 17.4.3. By Therapeutic Treatment
- 17.4.4. By End User
- 17.4.1. By Country
- 17.5. Market Attractiveness Analysis
- 17.5.1. By Country
- 17.5.2. By Type
- 17.5.3. By Therapeutic Treatment
- 17.5.4. By End User
- 17.6. Market Trends
- 17.7. Key Market Participants - Intensity Mapping
- 17.8. Drivers and Restraints - Impact Analysis
18. Middle East and Africa Statins Market Analysis 2019-2023 and Forecast 2024-2031
- 18.1. Introduction
- 18.2. Pricing Analysis
- 18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis by Market Taxonomy, 2019-2023
- 18.4. Market Size (US$ Mn) and Volume Forecast by Market Taxonomy, 2024-2031
- 18.4.1. By Country
- 18.4.1.1. GCC Countries
- 18.4.1.2. Turkey
- 18.4.1.3. Northern Africa
- 18.4.1.4. South Africa
- 18.4.1.5. Rest of Middle East and Africa
- 18.4.2. By Type
- 18.4.3. By Therapeutic Treatment
- 18.4.4. By End User
- 18.4.1. By Country
- 18.5. Market Attractiveness Analysis
- 18.5.1. By Country
- 18.5.2. By Type
- 18.5.3. By Therapeutic Treatment
- 18.5.4. By End User
- 18.6. Market Trends
- 18.7. Key Market Participants - Intensity Mapping
- 18.8. Drivers and Restraints - Impact Analysis
19. Emerging Countries Statins Market Analysis
- 19.1. Introduction
- 19.1.1. Market Value Proportion Analysis, By Key Countries
- 19.1.2. Global Vs. Country Growth Comparison
- 19.2. U.S. Statins Market Analysis
- 19.2.1. By Type
- 19.2.2. By Therapeutic Treatment
- 19.2.3. By End User
- 19.3. Canada Statins Market Analysis
- 19.3.1. By Type
- 19.3.2. By Therapeutic Treatment
- 19.3.3. By End User
- 19.4. Mexico Statins Market Analysis
- 19.4.1. By Type
- 19.4.2. By Therapeutic Treatment
- 19.4.3. By End User
- 19.5. Brazil Statins Market Analysis
- 19.5.1. By Type
- 19.5.2. By Therapeutic Treatment
- 19.5.3. By End User
- 19.6. Germany Statins Market Analysis
- 19.6.1. By Type
- 19.6.2. By Therapeutic Treatment
- 19.6.3. By End User
- 19.7. Italy Statins Market Analysis
- 19.7.1. By Type
- 19.7.2. By Therapeutic Treatment
- 19.7.3. By End User
- 19.8. France Statins Market Analysis
- 19.8.1. By Type
- 19.8.2. By Therapeutic Treatment
- 19.8.3. By End User
- 19.9. U.K. Statins Market Analysis
- 19.9.1. By Type
- 19.9.2. By Therapeutic Treatment
- 19.9.3. By End User
- 19.10. Spain Statins Market Analysis
- 19.10.1. By Type
- 19.10.2. By Therapeutic Treatment
- 19.10.3. By End User
- 19.11. BENELUX Statins Market Analysis
- 19.11.1. By Type
- 19.11.2. By Therapeutic Treatment
- 19.11.3. By End User
- 19.12. Russia Statins Market Analysis
- 19.12.1. By Type
- 19.12.2. By Therapeutic Treatment
- 19.12.3. By End User
- 19.13. China Statins Market Analysis
- 19.13.1. By Type
- 19.13.2. By Therapeutic Treatment
- 19.13.3. By End User
- 19.14. Japan Statins Market Analysis
- 19.14.1. By Type
- 19.14.2. By Therapeutic Treatment
- 19.14.3. By End User
- 19.15. S. Korea Statins Market Analysis
- 19.15.1. By Type
- 19.15.2. By Therapeutic Treatment
- 19.15.3. By End User
- 19.16. India Statins Market Analysis
- 19.16.1. By Type
- 19.16.2. By Therapeutic Treatment
- 19.16.3. By End User
- 19.17. ASEAN Statins Market Analysis
- 19.17.1. By Type
- 19.17.2. By Therapeutic Treatment
- 19.17.3. By End User
- 19.18. Australia and New Zealand Statins Market Analysis
- 19.18.1. By Type
- 19.18.2. By Therapeutic Treatment
- 19.18.3. By End User
- 19.19. GCC Countries Statins Market Analysis
- 19.19.1. By Type
- 19.19.2. By Therapeutic Treatment
- 19.19.3. By End User
- 19.20. Turkey Statins Market Analysis
- 19.20.1. By Type
- 19.20.2. By Therapeutic Treatment
- 19.20.3. By End User
- 19.21. Northern Africa Statins Market Analysis
- 19.21.1. By Type
- 19.21.2. By Therapeutic Treatment
- 19.21.3. By End User
- 19.22. South Africa Statins Market Analysis
- 19.22.1. By Type
- 19.22.2. By Therapeutic Treatment
- 19.22.3. By End User
20. Market Structure Analysis
- 20.1. Market Analysis by Tier of Companies (Linear Alpha-Olefins)
- 20.2. Market Share Analysis of Top Players
- 20.3. Market Presence Analysis
21. Competition Analysis
- 21.1. Competition Dashboard
- 21.2. Competition Benchmarking
- 21.3. Competition Deep Dive
- 21.3.1. Pfizer Inc.
- 21.3.1.1. Overview
- 21.3.1.2. Product Portfolio
- 21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
- 21.3.1.4. Sales Footprint
- 21.3.1.5. Strategy Overview
- 21.3.2. AstraZeneca plc
- 21.3.2.1. Overview
- 21.3.2.2. Product Portfolio
- 21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
- 21.3.2.4. Sales Footprint
- 21.3.2.5. Strategy Overview
- 21.3.3. Novartis International AG
- 21.3.3.1. Overview
- 21.3.3.2. Product Portfolio
- 21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
- 21.3.3.4. Sales Footprint
- 21.3.3.5. Strategy Overview
- 21.3.4. GlaxoSmithKline plc
- 21.3.4.1. Overview
- 21.3.4.2. Product Portfolio
- 21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
- 21.3.4.4. Sales Footprint
- 21.3.4.5. Strategy Overview
- 21.3.5. Merck & Co., Inc.
- 21.3.5.1. Overview
- 21.3.5.2. Product Portfolio
- 21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
- 21.3.5.4. Sales Footprint
- 21.3.5.5. Strategy Overview
- 21.3.6. Biocon
- 21.3.6.1. Overview
- 21.3.6.2. Product Portfolio
- 21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
- 21.3.6.4. Sales Footprint
- 21.3.6.5. Strategy Overview
- 21.3.7. Aurobindo Pharma Ltd
- 21.3.7.1. Overview
- 21.3.7.2. Product Portfolio
- 21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
- 21.3.7.4. Sales Footprint
- 21.3.7.5. Strategy Overview
- 21.3.8. Concord Biotech
- 21.3.8.1. Overview
- 21.3.8.2. Product Portfolio
- 21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
- 21.3.8.4. Sales Footprint
- 21.3.8.5. Strategy Overview
- 21.3.1. Pfizer Inc.
22. Assumptions and Acronyms Used
23. Research Methodology
